Supira Medical Closes Series E Financing to Support pVAD System

March 26, 2025—Supira Medical, Inc. announced that it completed a $120 million Series E financing round. The funds will be used to expand the company’s clinical programs for high-risk percutaneous coronary intervention (HRPCI) and cardiogenic shock in the percutaneous ventricular assist device (pVAD) market.

According to the press release, the company also recently completed enrollment in the prospective, single-arm SUPPORT I early feasibility study. Enrolling 15 patients across four clinical sites in the United States, the study evaluated the safety and feasibility of Supira’s pVAD in patients undergoing HRPCI.

The clinical expansion supported by the funding round also includes the SUPPORT II United States pivotal study for HRPCI, which will be used to seek FDA premarket approval for Supira pVAD.

The company also noted that it added Dr. Christopher Shen, Partner, Novo Holdings US to its Board of Directors.

The financing round was led by new investors Novo Holdings and Qatar Investment Authority, along with participation from two undisclosed strategic investors; also participating were existing investors Cormorant Asset Management and The Capital Partnership, 415 Capital, AMED Ventures, PA MedTech VC fund, and Unorthodox Ventures.